Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

24.4K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.4K
RNA Editing02:23

RNA Editing

9.6K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.6K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

376
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
376
Gene Therapy00:59

Gene Therapy

27.2K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple human transgenes prolong survival of triple-carbohydrate knockout porcine kidney xenografts in nonhuman primates.

Nature communications·2026
Same author

Intestinal resident effector-memory CD4 T cells on the adaptive-innate spectrum comprise IL-18 reactivity and adaptive CMV specificity.

Science advances·2026
Same author

MAIT cell responses to <i>S. aureus</i> and sensitivity to HlgAB are modulated by activation and tissue-dependent virulence effects.

bioRxiv : the preprint server for biology·2026
Same author

CXCR5 identifies stem-like resident memory CD8⁺ T cells enriched for latent EBV specificity in tonsils.

Science advances·2026
Same author

Transient tissue residency and lymphatic egress define human CD56<sup>bright</sup> NK cell homeostasis.

Nature immunology·2025
Same author

High torque Teno virus load is associated with increased all-cause mortality risk in liver transplant recipients: a multicenter cohort study.

Transplant immunology·2025

Related Experiment Video

Updated: Dec 23, 2025

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.0K

Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency.

Ahmad Karadagi1,2, Alex G Cavedon3, Helen Zemack1

  • 1Division of Transplantation Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.

Scientific Reports
|April 29, 2020
PubMed
Summary

Modified mRNA therapy shows promise for Alpha 1-antitrypsin (AAT) deficiency. This approach successfully produced functional AAT protein in liver cells and mice, offering a potential new treatment for AAT deficiency.

More Related Videos

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.9K

Related Experiment Videos

Last Updated: Dec 23, 2025

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.0K
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.9K

Area of Science:

  • Genetics and Molecular Biology
  • Hepatology
  • Pulmonology

Background:

  • Alpha 1-antitrypsin (AAT) deficiency is an inherited disorder caused by SERPINA1 gene mutations.
  • AAT deficiency leads to liver damage and lung emphysema due to uninhibited elastolytic activity.
  • Current treatments are limited, with AAT augmentation reserved for advanced lung disease.

Purpose of the Study:

  • To evaluate modified mRNA encoding human AAT as a potential therapeutic strategy.
  • To assess AAT expression and functional activity in vitro and in vivo.
  • To investigate the systemic delivery and efficacy of mRNA-based AAT therapy.

Main Methods:

  • Modified mRNA encoding human AAT was tested in primary human hepatocytes (including those from AAT-deficient patients).
  • AAT expression and secretion were quantified using ELISA and Western blot.
  • Functional activity was assessed via elastase activity assays.
  • mRNA formulated in lipid nanoparticles was delivered systemically to wild-type and AAT-deficient mouse models.

Main Results:

  • mRNA treatment significantly increased secreted AAT protein levels in cultured human hepatocytes (1.14 to 3.43 µg/ml).
  • The translated AAT protein demonstrated protease inhibitory function.
  • Systemic intravenous delivery of mRNA in mice resulted in hepatic uptake and functional protein production.

Conclusions:

  • Modified mRNA therapy can successfully produce functional AAT protein in human hepatocytes and in vivo.
  • Systemic mRNA delivery demonstrates potential for treating Alpha 1-antitrypsin deficiency.
  • This approach offers a promising new therapeutic avenue for AAT deficiency patients.